News•Apr 18, 2026
Links (96)
Recent developments highlight mixed outcomes across health and technology. Monoclonal antibodies targeting amyloid‑beta continue to underperform in Alzheimer trials, while a 13‑week rapamycin study failed to meet its primary endpoints. Meanwhile, AI‑driven writing constitutions sparks debate, meditation research reports a sense of timelessness, and epidemiologists note a rising incidence of colorectal cancer among younger adults. These disparate findings underscore ongoing challenges in biomedical innovation and emerging tech ethics.
